Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease

Table 2 Summary of the clinical parameters of patients with rheumatoid arthritis

	Responders	Non- or moderate responders	Responders	Non- or moderate responders
	Test cohort		Validation cohort		Difference
At baseline	6	13	4	11
Gender (male/female)	1/5	2/11	0/4	3/8
Age (years)	44.3±9.3	47±10.7	54±17	56.2±6.8	Non-significant
DAS28	5.6±0.3	5.2±0.7	5.2±0.06	5.4±0.5	Non-significant
HAQ	1.2±0.7	2±0.6	1.5±1.1	1.9±0.7	Non-significant
CRP (mg/ml)	16.8±18.3	28.3±23.8	18.9±18.3	9.5±10.3	Non-significant
DMARDs	2.8±0.9	2.6±0.7	3±0.8	2.7±1.4	Non-significant

CRP, C-reactive protein;DAS28, Disease Activity Score; HAQ, Health Assessment Questionnaire; DMARD, disease-modifying anti-rheumatic drug (methotrexate). Data are shown as mean±SD.

ISSN: 1756-994X